Objective: Case description of recurrent idiopathic intracranial hypertension (IIH) in a transgender man on gender-affirming hormone therapy. Methods: Case report. Results: A 24-year-old transmasculine patient (assigned female at birth), with a body mass index (BMI) of 37.3, presented with headaches, transient visual obscurations (TVOs), pulsatile tinnitus, Frisén 5 papilledema, and scotomas. He was diagnosed with IIH after normal magnetic resonance imaging (MRI) and magnetic resonance venogram (MRV), an elevated opening pressure of 27 cm water, and normal cerebrospinal fluid studies. IIH resolved with acetazolamide and optic nerve sheath fenestration (ONSF). He then started gender-affirming testosterone therapy and was on this for 20 months when his headaches, pulsatile tinnitus, TVOs, and Frisén 3 papilledema recurred at a BMI of 31. Brain MRI and MRV were normal. Opening pressure was elevated at 31 cm. water. Acetazolamide 4 g/day did not improve the papilledema, thus a left ONSF was repeated resulting in eventual resolution of the IIH. Discussion: Several reports have been published of IIH development in patients receiving testosterone therapy. Hormone prescribers for gender affirmation may wish to screen for visual loss and optic nerve edema in patients undergoing testosterone therapy, which may also stimulate appetite weight gain.
Objective: Case description of recurrent idiopathic intracranial hypertension (IIH) in a transgender man on gender-affirming hormone therapy. Methods: Case report. Results: A 24-year-old transmasculine patient (assigned female at birth), with a body mass index (BMI) of 37.3, presented with headaches, transient visual obscurations (TVOs), pulsatile tinnitus, Frisén 5 papilledema, and scotomas. He was diagnosed with IIH after normal magnetic resonance imaging (MRI) and magnetic resonance venogram (MRV), an elevated opening pressure of 27 cm water, and normal cerebrospinal fluid studies. IIH resolved with acetazolamide and optic nerve sheath fenestration (ONSF). He then started gender-affirming testosterone therapy and was on this for 20 months when his headaches, pulsatile tinnitus, TVOs, and Frisén 3 papilledema recurred at a BMI of 31. Brain MRI and MRV were normal. Opening pressure was elevated at 31 cm. water. Acetazolamide 4 g/day did not improve the papilledema, thus a left ONSF was repeated resulting in eventual resolution of the IIH. Discussion: Several reports have been published of IIH development in patients receiving testosterone therapy. Hormone prescribers for gender affirmation may wish to screen for visual loss and optic nerve edema in patients undergoing testosterone therapy, which may also stimulate appetite weight gain.
Authors: Catherine Hornby; Susan P Mollan; James Mitchell; Keira Annie Markey; Andreas Yangou; Ben L C Wright; Michael W O'Reilly; Alexandra J Sinclair Journal: Neuroophthalmology Date: 2017-05-10
Authors: Catherine Hornby; Susan P Mollan; Hannah Botfield; Michael W OʼReilly; Alexandra J Sinclair Journal: J Neuroophthalmol Date: 2018-12 Impact factor: 3.042
Authors: Michael W O'Reilly; Connar Sj Westgate; Catherine Hornby; Hannah Botfield; Angela E Taylor; Keira Markey; James L Mitchell; William J Scotton; Susan P Mollan; Andreas Yiangou; Carl Jenkinson; Lorna C Gilligan; Mark Sherlock; James Gibney; Jeremy W Tomlinson; Gareth G Lavery; David J Hodson; Wiebke Arlt; Alexandra J Sinclair Journal: JCI Insight Date: 2019-03-21